Meu SciELO
Serviços Personalizados
Artigo
Indicadores
Citado por SciELO
Links relacionados
Similares em SciELO
Compartilhar
Revista Cubana de Investigaciones Biomédicas
versão On-line ISSN 1561-3011
Resumo
ALERM GONZALEZ, Alina et al. Respuesta pos-vacunal y persistencia de anticuerpos contra el virus de la hepatitis B en niños asmáticos y no asmáticos vacunados con eberbiovac-HB. Rev Cubana Invest Bioméd [online]. 2000, vol.19, n.1, pp. 91-105. ISSN 1561-3011.
The presence of anti-AgsHB antibodies was studied in 1 280 children aged from 7 months to 3 years, who were administered the Cuban anti-hepatitis B vaccine Heberbiovac HB when they were born, at 1 and 6 months of age as part of the National Immunization Program in Cuba. AgsHB was detected and serum antibodies were determined by ELISA sandwich methods, developed and validated in the Immunology Laboratory. Considering the time elapsed from the end of the vaccination, the sample was divided into 3 groups: 7 months to 1 year, 1-2 years, and 2-3 years of age. None of the children exhibited infection markers and seroprotection percentages were 96.6 in 7months to 1 year old group, and 100% in 1-2 years-old and 2-3 years-old groups. The percentages of children with anti-HbsAg values equal to or over 100 UI/L were 93.1%, 90.7% and 77.8% respectively. The geometric means of anti-HbsAg were 1 0567, 699 and 483 UI/L respectively. Significant differences were found in seroprotection and hyperesponse percentages and in anti-HbsAg geometric means when comparing these variables between children with bronchial asthma history (687.8, 620.2 and 402.9 UI/L) and non-asthmatic children of the 3 groups(1 341, 1 047.8 and 528.3 UI/L); the concentrations were much higher in non-asthmatics. These outcomes could signal that even with non-allergenic antigens, a predominant Th2 response may be induced in asthmatic children and that wither antibodies are not detected due to IgE cytophilia or response is in fact lower as a result of the disreactor nature of the asthmatics. It is concluded that immunogenicity of the vaccine in a population is comparable to that of the controlled studies and that a reinforcement dose is not needed at least 4 years after the completion of the immunization schedule if one takes into account the kinetics of anti-HbsAg elimination. A controlled study of asthmatic populations is required to verify the achieved results with due explanations
Palavras-chave : HEPATITIS B VACCINES [immunology]; ASTHMA [blood]; HEPATITIS B SURFACE ANTIGENS [analysis]; MASS VACCINATION; IMMUNIZATION PROGRAMS; CUBA.